In July, the FDA issued a complete response letter (CRL) for Replimune's biologics license application for RP1 (vusolimogene oderparepvec), an oncolytic immunotherapy, combined with nivolumab (Opdivo) ...

A major achievement with far-reaching implications for treating deadly skin cancer has been discovered by Tel Aviv University ...

The anti-tumor immune response involves a series of complex steps mediated by various immune cells and signaling molecules.

Investigators evaluated the efficacy and safety of toripalimab versus dacarbazine as the first-line treatment in advanced melanoma predominantly of acral subtype.

Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety ...

With a $1 million grant, University of Auckland scientists hope to change the lives of hundreds of Kiwis who lose their lives ...

First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...

A new international study led by the Gray Faculty of Medical & Health Sciences at Tel Aviv University finds: melanoma cancer cells paralyze immune cells by secreting extracellular vesicles (EVs), ...

Why are clinical trials in radiation oncology important? If you or a loved one is going through treatment for cancer, you may have wondered about clinical trials. How do they benefit patients? How ...